Algiax Pharmaceuticals erforscht und realisiert innovative Produkte zur Behandlung von Krankheiten mit einem hohen ungedeckten medizinischen Bedarf. Kern der Entwicklung ist AP-325, ein niedermolekularer GABAA-Rezeptor-Modulator, der sich in der klinischen Entwicklung als Therapie für neuropathische Schmerzen befindet.
Location: Germany, North Rhine-Westphalia, Erkrath
Employees: 1-10
Total raised: $5.47M
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | OCCIDENT | occident.g... |
| - | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.05.2012 | - | $5.47M | - |
Mentions in press and media 2
| Date | Title | Description |
| 09.12.2019 | Early-stage cancer biotech nails $85M C round; Flemming Ornskov's Galderma scores 'breakthrough' status | → Zentalis Pharmaceuticals just nabbed an $85 million round from a syndicate that includes Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Surveyor Capital and Even... |
| 16.05.2012 | Algiax Pharmaceuticals Raises €4.3M in Funding | Algiax Pharmaceuticals GmbH, an Erkrath, Germany-based developer of an advanced therapy for Neuropathic pain, has raised €4.3m in funding. Backers include High-Tech Gründerfonds, Private Investors and KfW. Founded in July 2011 by Dr. Jürgen... |